1. Autophagy
  2. Autophagy

Autophagy

Autophagy is a lysosome-dependent degradative process that protects cancer cells from multiple stresses.

Autophagy, the sequestration of organelles and proteins in autophagic vesicles (AVs) and degradation of this cargo through lysosomal fusion, allows tumor cells to survive metabolic and therapeutic stresses. Therapy-induced autophagy is a key resistance mechanism to many anticancer agents, and autophagy levels are increased in most cancers. Chloroquine derivatives block autophagy by impairing lysosomal function.

Autophagy plays an emerging role in immune responses against intracellular pathogens and regulates distinct immunologic processes, important for the initiation of potent innate or adaptive immune responses.

Autophagy is important for the transport of cytoplasmic constituents such as damaged mitochondria and protein aggregates to lysosomes where they are degraded and recycled back into the cytoplasm.

Autophagy Related Products (561):

Cat. No. Product Name Effect Purity
  • HY-19312
    3-Methyladenine Inhibitor 99.84%
    3-Methyladenine is a potent inhibitor of autophagy and PI3K, blocking autophagy through its effect on PI3K, with IC50s of 25 μM and 60 μM for Vps34 and PI3Kγ, respectively.
  • HY-10108
    LY294002 Inhibitor 99.95%
    LY294002 is a broad-spectrum inhibitor of PI3K, with IC50 of 0.5/0.57/0.97 μM for PI3Kα/PI3Kδ/PI3Kβ, respectively, also potently inhibits CK2 with IC50 of 98 nM.
  • HY-11109
    TAK-242 Inhibitor 99.95%
    TAK-242 is a potent TLR4 signaling inhibitor, selectively inhibits the TLR4-mediated production of cytokines and NO.
  • HY-13030
    (+)-JQ-1 Activator 99.90%
    (+)-JQ-1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for the first and second bromodomain (BRD4(1/2)).
  • HY-12041
    SP600125 Inhibitor 98.69%
    SP600125 is a broad-spectrum JNK inhibitor for JNK1, JNK2 and JNK3 with IC50 of 40 nM, 40 nM and 90 nM, respectively.
  • HY-111383
    LX2343 Activator 99.86%
    LX2343 is a BACE1 enzyme inhibitor with an IC50 value of 11.43±0.36 μM. LX2343 acts as a non-ATP competitive PI3K inhibitor with an IC50 of 15.99±3.23 μM. LX2343 stimulates autophagy in its promotion of clearance.
  • HY-10162
    Olaparib Activator 99.71%
    Olaparib is a potent PARP inhibitor with IC50 of 5 and 1 nM for PARP-1 and PARP-2, respectively.
  • HY-10256
    SB 203580 Activator 99.54%
    SB 203580 is a p38 MAPK inhibitor with IC50 of 0.3-0.5 μM, also blocks PKB phosphorylation with IC50 of 3-5 μM.
  • HY-15142
    Doxorubicin hydrochloride Activator 99.47%
    Doxorubicin hydrochloride is a Topoisomerase II (Top2) catalytic inhibitor, also is a broad spectrum antibiotic used in the treatment of cancers, with IC50 of 374 nM for Hela cells.
  • HY-12031
    U0126 Inhibitor 98.03%
    U0126 is a non-ATP competitive MEK inhibitor, with IC50 of 70 nM and 60 nM for MEK1 and MEK2, respectively.
  • HY-70002
    Enzalutamide Activator 99.71%
    Enzalutamide is an androgen-receptor (AR) antagonist with IC50 of 36 nM in LNCaP cells.
  • HY-17589
    Chloroquine diphosphate Inhibitor 99.94%
    Chloroquine (diphosphate) is an antimalarial drug and autophagy/lysosome inhibitor, inhibiting Toll-like receptor (TLR) signalling.
  • HY-10227
    Bortezomib Modulator 99.97%
    Bortezomib is a potent 20S proteasome inhibitor with Ki of 0.6 nM.
  • HY-13418
    Dorsomorphin dihydrochloride Inhibitor 99.73%
    Dorsomorphin dihydrochloride is a potent and selective AMPK inhibitor, that is competitive with ATP, with Ki of 109±16 nM in the absence of AMP.
  • HY-10182
    CHIR-99021 Activator 99.92%
    CHIR-99021 is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; > 500-fold selectivity for GSK-3 versus its closest homologs CDC2 and ERK2, as well as other protein kinases.
  • HY-10358
    MK 2206 dihydrochloride Activator 99.47%
    MK 2206 is an orally active allosteric Akt inhibitor with IC50 of 5 nM/12 nM/65 nM for Akt1/Akt2/Akt3, respectively.
  • HY-10201
    Sorafenib Activator 99.83%
    Sorafenib is a potent multikinase inhibitor with IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.
  • HY-17471A
    Metformin hydrochloride Activator 99.98%
    Metformin (hydrochloride) is a first-line drug for the treatment of type 2 diabetes and there is increasing evidence of a potential efficacy of this agent as an anti-cancer drug.
  • HY-12028
    PD98059 Inhibitor 99.45%
    PD98059 is a MEK inhibitor with IC50 of 5 μM, also suppresses TCDD binding to the aryl hydrocarbon receptor (AHR) with IC50 of 4 μM.
  • HY-50895
    Gefitinib Activator 99.89%
    Gefitinib is an inhibitor that specifically binds and inhibits the EGFR tyrosine kinase, with the IC50 value of 2-37 nM in NR6wtEGFR cells.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.